רווח למניה בשנים עשר החודשים האחרונים: radiopharmtheranostics.com (RADX)

Radiopharm Theranostics (RADX) is currently in the pre-revenue stage with high capital expenditures. The company's competitive advantage lies in its unique isotopes used to combat aggressive tumors. Experienced management is currently scaling the international asset portfolio. The change in rolling net income per share demonstrates demand inertia, with the metric value standing at -3.18, which is critical to consider to minimize the risk of capital drawdown.

Radiopharm Theranostics (RADX) is scaling a high-precision radiopharmaceutical ecosystem that integrates cancer diagnostics and therapy. The eps_ttm_co metric reflects the final net income allocated per share over a trailing twelve-month period. This indicator measures the actual efficiency of business capitalization, stripped of the influence of total issuance volume. It is critical for investors to evaluate this profit profile within the context of the debt load. The history of the EPS TTM figure allows for the determination of the company's fundamental margin of safety.